Immunity after yellow fever vaccination in HIV positive travelers - YELLAR study

Completed

• Conditions: Yellow Fever Infection; 10047438

• Registration Number: NL-OMON39974
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

> 18 years
Indication for first yellow fever vaccination
Travel to a yellow fever endemic area within one year
Stable CD4 counts between 200 and 500 for at least two one year (2 measurements at half yearly clinical visits) and certain travel to yellow fever endemic area, even if travel has not been planned.

Exclusion Criteria

< 18 years
Previous yellow fever vaccination

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The height and duration of viraemia, the seroconversion rate and the level of<br /><br>neutralising antibodies in relation to:<br /><br>- the actual number of CD4 positive cells<br /><br>- the nadir of CD4 positive cells<br /><br>- the duration of CD4 count above 200<br /><br>- and the viral load of HIV</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Local and systemic side effects of yellow fever vaccination in HIV positive<br /><br>patients.<br /><br>A comparison of all endpoints in the HIV positive group compared to the healthy<br /><br>controls.</p><br>